Organization
Stanford University, Palo Alto, CA, United States of America
3 abstracts
Abstract
ASSOCIATION BETWEEN LOW HEMOGLOBIN AND RADIOGRAPHIC PROGRESSION OVER 52 WEEKS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL OF SARILUMABOrg: Charité – University Medicine Berlin, Berlin, Germany, Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States of America, Sanofi, Bridgewater, NJ, United States of America, Sanofi Genzyme, Cambridge, MA, United States of America, Stanford University, Palo Alto, CA, United States of America,
Abstract
ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIESOrg: Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, United States of America, NYU Langone Health, New York, NY, United States of America, Stanford University, Palo Alto, CA, United States of America, Sarasota Arthritis Research Center, Sarasota, FL, United States of America, Sanofi Genzyme, Cambridge, MA, United States of America,
Abstract
ASSOCIATION OF SERUM MARKERS WITH CLINICAL RESPONSE MEASURES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB, A HUMAN ANTI-TNF ALPHA MONOCLONAL ANTIBODY Org: Centocor Research & Development, Inc, Malvern, Centocor Research & Development, Inc/U of Penn, Malvern/Phila, Stanford University, Palo Alto, CA, United States of America, Mayo Clinic, Rochester, MN, Division of Medical Oncology, Mayo Clinic, Rochester, MN, University of Massachusetts Medical School, Worcester, MA, United States,